ேசை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ேசை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant ....
(0) TOKYO, May 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and ITO EN, LTD. announced today that both parties have entered into a business alliance agreement concerning the initiatives for supporting people living with and preventing dementia with the aim of realizing a healthy and long-lived society. Through this alliance, Eisai and ITO EN aim to contribute to the solution of dementia, which is one of the important social issues, with integrating Eisai s wealth of experience and knowledge in drug creation and disease awareness activities in the area of dementia, as well as Eisai s solution measures such as digital technology, and ITO EN s customer network through its community-based sales activities, as well as ITO EN s problem-solving project related to cognitive function based on abundant research on Matcha (powdered green tea). The specific initiatives planned are as follows. ....
Eisai and National Cancer Center Commence Joint Research and Development Project Using PDX With High Predictability of Clinical Outcomes, and Cancer Genome Data TOKYO, May 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. and the National Cancer Center Japan announced today that both parties have entered into a joint research and development (R&D) agreement concerning Basic research on the drug discovery and development to accelerate development of anticancer drugs in treatment of patients with rare cancers and refractory cancers , and that research activities have commenced. This R&D project is to be carried out with funding under the program Cyclic Innovation for Clinical Empowerment (CiCLE) established by the Japan Agency for Medical Research and Development (AMED). ....
(1) TOKYO, Mar 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer s disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer s and Parkinson s Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021. Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally. Regarding aducanumab, for which applications are currently underway in the U.S., Europe and Japan, Biogen Inc. will conduct presentations on the correlation of amyloid PET and cerebrospinal fluid (CSF) biomarkers in the Phase III studies (EMERGE/ENGAGE), as well as evaluations of the safety and efficacy of aducanumab in early AD. Lecanemab and aducanumab ....
Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya TOKYO, Mar 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya. CA Medlynks Kenya, Ltd., in collaboration with the government of Meru County in Kenya, will support the setup of PCR testing laboratories, along with procurement of equipment necessary for testing and training of screening technicians. ....